Probi probiotics reduce bowel problems linked to cancer radiation therapy
PRESS RELEASE
A randomized, double-blind, placebo-controlled trial with Probi’s two probiotic strains, HEAL9MTand LP6595, has been shown to reduce gastrointestinal problems in women receiving pelvic radiation therapy.
The 3-arm study included 75 women with gynecological cancer receiving pelvic radiation therapy. Patients received a high or low dose of the HEAL9 combination probiotic strainsMTand LP6595 or placebo and was conducted at two sites in Sweden.
“When receiving radiation therapy for gynecological cancer, women often experience gastrointestinal problems during and after therapy. This study showed a significant reduction in the severity and frequency of abdominal pain and urgency of defecation.” ExplainNiklas Larsson, Senior Director of Scientific Affairs and Intellectual Property at Probi.
“It is extremely gratifying to see that such a vulnerable group can be helped in a highly exposed situation by consuming our probiotic strains. This fits perfectly with our vision to provide probiotics for healthier living by being an innovative precursor,” says Tom Rönnlund, CEO of Probi.
The study “Decreasing the Adverse Effects in Pelvic Radiation Therapy: A Randomized Controlled Trial Evaluating the Use of Probiotics” was recently published in Advances in Radiation Oncology(2022) 8, 101089 and can be found here: https://doi.org/10.1016/j.adro.2022.101089
For more information, please contact:
Tom Rönnlund, CEO, Probi®
Telephone: +46 46 286 89 40, Email: trd@probi.com
Niklas Larsson, Senior Director of Scientific Affairs and Intellectual Property, Probi®
Telephone: +46 76 118 26 99, Email: niklas.larsson@probi.com
Charlotte Beyerholm, Marketing & Global Communication Director, Probi®
Phone: +46 76 870 94 65, Email: charlotte.beyerholm@probi.com
ABOUT PROBI
Probi®is a global company that focuses exclusively on the research, manufacture and supply of probiotics for
supplements and functional foods. We are experts in managing stable live bacteria, from R&D to all
stage of the manufacturing process and are dedicated to bringing the health benefits of probiotics
available to people everywhere. Our health concepts, formulations and formats are backed by strong
Documentation. Since our founding in 1991 at the Swedish University of Lund, Probi has expanded its activities to
more than 40 markets. We hold over 400 patents worldwide. Read more on www.probi.com.
Probi®is a registered trademark and HEAL9MTis a registered trademark of Probi AB.
Comments are closed.